FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002747018> ?p ?o ?g. }

• W3002747018 endingPage "497" @default.
• W3002747018 startingPage "487" @default.
• W3002747018 abstract "Background The incidence of infective endocarditis related to injection drug use is increasing. On the basis of clinical practice and epidemiological and in-vitro data, we postulated that exposure to controlled-release hydromorphone is associated with an increased risk of infective endocarditis among people who inject drugs. Methods We used linked health administrative databases in Ontario, Canada, to assemble a retrospective cohort of adults (aged 18–55 years) who inject drugs for the period of April 1, 2006, to Sept 30, 2015. Cases of infective endocarditis among this cohort were identified using International Classification of Diseases 10 codes. We estimated exposure to hydromorphone and risk of infective endocarditis among this cohort in two ways. First, in a population-level analysis, we identified patients living in regions with high (≥25%) and low (≤15%) hydromorphone prescription rates and, after matching 1:1 on various baseline characteristics, compared their frequency of infective endocarditis. Second, in a patient-level analysis including only those with prescription drug data, we identified those who had filled prescriptions (ie, received the drug from the pharmacy) for controlled-release or immediate-release hydromorphone and, after matching 1:1 on various baseline characteristics, compared their frequency of infective endocarditis with that of patients who had filled prescriptions for other opioids. Results Between April 1, 2006, and Sept 30, 2015, 60 529 patients had evidence of injection drug use, 733 (1·2%, 95% CI 1·1–1·3) of whom had infective endocarditis. In the population-level analysis of 32 576 matched patients, we identified 254 (1·6%) admissions with infective endocarditis in regions with high hydromorphone use and 113 (0·7%) admissions in regions with low use (adjusted odds ratio [OR] 2·2, 95% CI 1·8–2·8, p<0·0001). In the patient-level analysis of 3884 matched patients, the frequency of infective endocarditis was higher among patients who filled prescriptions for hydromorphone than among those who filled prescriptions for non-hydromorphone opioids (2·8% [109 patients] vs 1·1% [41 patients]; adjusted OR 2·5, 95% CI 1·8–3·7, p<0·0001). This significant association was seen for controlled-release hydromorphone (3·9% [73 of 1895 patients] vs 1·1% [20 of 1895]; adjusted OR 3·3, 95% CI 2·1–5·6, p<0·0001), but not for immediate-release hydromorphone (1·8% [36 of 1989] vs 1·1% [21 of 1989]; 1·7, 0·9–3·6, p=0·072. Interpretation Among people who inject drugs, the risk of infective endocarditis is significantly higher for those exposed to controlled-release hydromorphone than to other opioids. This association might be mediated by the controlled-release mechanism and should be the subject of further investigation. Funding Ontario Ministry of Health and Long-Term Care, Academic Medical Organization of Southwestern Ontario, Schulich School of Medicine and Dentistry (Western University), and Lawson Health Research Institute. The incidence of infective endocarditis related to injection drug use is increasing. On the basis of clinical practice and epidemiological and in-vitro data, we postulated that exposure to controlled-release hydromorphone is associated with an increased risk of infective endocarditis among people who inject drugs. We used linked health administrative databases in Ontario, Canada, to assemble a retrospective cohort of adults (aged 18–55 years) who inject drugs for the period of April 1, 2006, to Sept 30, 2015. Cases of infective endocarditis among this cohort were identified using International Classification of Diseases 10 codes. We estimated exposure to hydromorphone and risk of infective endocarditis among this cohort in two ways. First, in a population-level analysis, we identified patients living in regions with high (≥25%) and low (≤15%) hydromorphone prescription rates and, after matching 1:1 on various baseline characteristics, compared their frequency of infective endocarditis. Second, in a patient-level analysis including only those with prescription drug data, we identified those who had filled prescriptions (ie, received the drug from the pharmacy) for controlled-release or immediate-release hydromorphone and, after matching 1:1 on various baseline characteristics, compared their frequency of infective endocarditis with that of patients who had filled prescriptions for other opioids. Between April 1, 2006, and Sept 30, 2015, 60 529 patients had evidence of injection drug use, 733 (1·2%, 95% CI 1·1–1·3) of whom had infective endocarditis. In the population-level analysis of 32 576 matched patients, we identified 254 (1·6%) admissions with infective endocarditis in regions with high hydromorphone use and 113 (0·7%) admissions in regions with low use (adjusted odds ratio [OR] 2·2, 95% CI 1·8–2·8, p<0·0001). In the patient-level analysis of 3884 matched patients, the frequency of infective endocarditis was higher among patients who filled prescriptions for hydromorphone than among those who filled prescriptions for non-hydromorphone opioids (2·8% [109 patients] vs 1·1% [41 patients]; adjusted OR 2·5, 95% CI 1·8–3·7, p<0·0001). This significant association was seen for controlled-release hydromorphone (3·9% [73 of 1895 patients] vs 1·1% [20 of 1895]; adjusted OR 3·3, 95% CI 2·1–5·6, p<0·0001), but not for immediate-release hydromorphone (1·8% [36 of 1989] vs 1·1% [21 of 1989]; 1·7, 0·9–3·6, p=0·072. Among people who inject drugs, the risk of infective endocarditis is significantly higher for those exposed to controlled-release hydromorphone than to other opioids. This association might be mediated by the controlled-release mechanism and should be the subject of further investigation." @default.
• W3002747018 created "2020-01-30" @default.
• W3002747018 creator A5000457974 @default.
• W3002747018 creator A5001731019 @default.
• W3002747018 creator A5003130882 @default.
• W3002747018 creator A5012927159 @default.
• W3002747018 creator A5030762655 @default.
• W3002747018 creator A5085876066 @default.
• W3002747018 date "2020-04-01" @default.
• W3002747018 modified "2023-09-25" @default.
• W3002747018 title "Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study" @default.
• W3002747018 cites W1866803133 @default.
• W3002747018 cites W1971551916 @default.
• W3002747018 cites W2040370096 @default.
• W3002747018 cites W2048426578 @default.
• W3002747018 cites W2049491523 @default.
• W3002747018 cites W2122109727 @default.
• W3002747018 cites W2124163887 @default.
• W3002747018 cites W2129581375 @default.
• W3002747018 cites W2132989145 @default.
• W3002747018 cites W2141661484 @default.
• W3002747018 cites W2143119845 @default.
• W3002747018 cites W2167561774 @default.
• W3002747018 cites W2509413775 @default.
• W3002747018 cites W2513312192 @default.
• W3002747018 cites W2519124418 @default.
• W3002747018 cites W2560787960 @default.
• W3002747018 cites W2587845606 @default.
• W3002747018 cites W2772989883 @default.
• W3002747018 cites W2777308280 @default.
• W3002747018 cites W2779386198 @default.
• W3002747018 cites W2783726333 @default.
• W3002747018 cites W2793034333 @default.
• W3002747018 cites W2808092861 @default.
• W3002747018 cites W2891507238 @default.
• W3002747018 cites W2895993975 @default.
• W3002747018 cites W2902842760 @default.
• W3002747018 cites W2902849424 @default.
• W3002747018 cites W2906591149 @default.
• W3002747018 cites W2908512014 @default.
• W3002747018 cites W2911251964 @default.
• W3002747018 cites W2940746649 @default.
• W3002747018 cites W2941300355 @default.
• W3002747018 cites W2949911447 @default.
• W3002747018 doi "https://doi.org/10.1016/s1473-3099(19)30705-4" @default.
• W3002747018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31981474" @default.
• W3002747018 hasPublicationYear "2020" @default.
• W3002747018 type Work @default.
• W3002747018 sameAs 3002747018 @default.
• W3002747018 citedByCount "21" @default.
• W3002747018 countsByYear W30027470182020 @default.
• W3002747018 countsByYear W30027470182021 @default.
• W3002747018 countsByYear W30027470182022 @default.
• W3002747018 countsByYear W30027470182023 @default.
• W3002747018 crossrefType "journal-article" @default.
• W3002747018 hasAuthorship W3002747018A5000457974 @default.
• W3002747018 hasAuthorship W3002747018A5001731019 @default.
• W3002747018 hasAuthorship W3002747018A5003130882 @default.
• W3002747018 hasAuthorship W3002747018A5012927159 @default.
• W3002747018 hasAuthorship W3002747018A5030762655 @default.
• W3002747018 hasAuthorship W3002747018A5085876066 @default.
• W3002747018 hasConcept C107130276 @default.
• W3002747018 hasConcept C120665830 @default.
• W3002747018 hasConcept C121332964 @default.
• W3002747018 hasConcept C126322002 @default.
• W3002747018 hasConcept C167135981 @default.
• W3002747018 hasConcept C170493617 @default.
• W3002747018 hasConcept C187212893 @default.
• W3002747018 hasConcept C201903717 @default.
• W3002747018 hasConcept C2426938 @default.
• W3002747018 hasConcept C2775872228 @default.
• W3002747018 hasConcept C2779158186 @default.
• W3002747018 hasConcept C2780176578 @default.
• W3002747018 hasConcept C2781063702 @default.
• W3002747018 hasConcept C2908647359 @default.
• W3002747018 hasConcept C61511704 @default.
• W3002747018 hasConcept C71924100 @default.
• W3002747018 hasConcept C72563966 @default.
• W3002747018 hasConcept C98274493 @default.
• W3002747018 hasConcept C99454951 @default.
• W3002747018 hasConceptScore W3002747018C107130276 @default.
• W3002747018 hasConceptScore W3002747018C120665830 @default.
• W3002747018 hasConceptScore W3002747018C121332964 @default.
• W3002747018 hasConceptScore W3002747018C126322002 @default.
• W3002747018 hasConceptScore W3002747018C167135981 @default.
• W3002747018 hasConceptScore W3002747018C170493617 @default.
• W3002747018 hasConceptScore W3002747018C187212893 @default.
• W3002747018 hasConceptScore W3002747018C201903717 @default.
• W3002747018 hasConceptScore W3002747018C2426938 @default.
• W3002747018 hasConceptScore W3002747018C2775872228 @default.
• W3002747018 hasConceptScore W3002747018C2779158186 @default.
• W3002747018 hasConceptScore W3002747018C2780176578 @default.
• W3002747018 hasConceptScore W3002747018C2781063702 @default.
• W3002747018 hasConceptScore W3002747018C2908647359 @default.
• W3002747018 hasConceptScore W3002747018C61511704 @default.
• W3002747018 hasConceptScore W3002747018C71924100 @default.
• W3002747018 hasConceptScore W3002747018C72563966 @default.
• W3002747018 hasConceptScore W3002747018C98274493 @default.

• next